Norges Bank Acquires New Position in Insulet Corporation $PODD

Norges Bank bought a new position in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,033,450 shares of the medical instruments supplier’s stock, valued at approximately $324,689,000. Norges Bank owned approximately 1.47% of Insulet at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PODD. Cetera Investment Advisers increased its stake in shares of Insulet by 167.0% in the first quarter. Cetera Investment Advisers now owns 6,455 shares of the medical instruments supplier’s stock worth $1,695,000 after purchasing an additional 4,037 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in Insulet by 39.9% in the 1st quarter. Mackenzie Financial Corp now owns 10,576 shares of the medical instruments supplier’s stock worth $2,777,000 after buying an additional 3,015 shares during the period. Natixis Advisors LLC increased its stake in Insulet by 33.9% in the 1st quarter. Natixis Advisors LLC now owns 59,412 shares of the medical instruments supplier’s stock worth $15,602,000 after buying an additional 15,041 shares in the last quarter. Alberta Investment Management Corp increased its stake in Insulet by 144.1% in the 1st quarter. Alberta Investment Management Corp now owns 8,300 shares of the medical instruments supplier’s stock worth $2,180,000 after buying an additional 4,900 shares in the last quarter. Finally, Commerce Bank raised its holdings in Insulet by 239.4% during the first quarter. Commerce Bank now owns 13,192 shares of the medical instruments supplier’s stock valued at $3,464,000 after acquiring an additional 9,305 shares during the period.

Insider Transactions at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The SEC filing for this sale provides additional information. 0.39% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on PODD shares. JPMorgan Chase & Co. upped their price objective on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Barclays upped their price target on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Royal Bank Of Canada increased their price objective on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Rothschild & Co Redburn boosted their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Finally, Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $379.65.

Insulet Trading Up 0.1%

PODD stock opened at $327.09 on Monday. The firm has a fifty day moving average price of $321.98 and a 200 day moving average price of $316.33. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88. The firm has a market cap of $23.01 billion, a PE ratio of 99.42, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. During the same quarter last year, the business earned $1.08 earnings per share. Insulet’s quarterly revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.